Journal profile · Psychiatry
Human Psychopharmacology Clinical and Experimental
ISSN 0885-6222 · eISSN 1099-1077 · John Wiley and Sons Ltd · ENGLAND · Bimonthly · Founded 1986
Human Psychopharmacology Clinical and Experimental: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 1.95; hybrid open access; APC about USD 4,030; median 112 days to acceptance (63 articles, last 24 months); community-reported acceptance: fairly easy; 37 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Human Psychopharmacology Clinical and Experimental is published by John Wiley and Sons Ltd and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Treatment of Major Depression, Schizophrenia research and treatment and Neurotransmitter Receptor Influence on Behavior, together about 32.5% of its articles. Its main subfields are Psychiatry and Mental health. (generated from OpenAlex topic counts and CAS ranking data)
Human Psychopharmacology: Clinical and Experimental provides a forum for the evaluation of clinical and experimental research on both new and established psychotropic medicines. Experimental studies of other centrally active drugs, including herbal products, in clinical, social and psychological contexts, as well as clinical/scientific papers on drugs of abuse and drug dependency will also be considered. While the primary purpose of the Journal is to publish the results of clinical research, the results of animal studies relevant to human psychopharmacology are welcome. The following topics are of special interest to the editors and readers of the Journal: All aspects of clinical psychopharmacology Efficacy and safety studies of novel and standard psychotropic drugs Studies of the adverse effects of psychotropic drugs Effects of psychotropic drugs on normal physiological processes Geriatric and paediatric psychopharmacology Ethical and psychosocial aspects of drug use and misuse Psychopharmacological aspects of sleep and chronobiology Neuroimaging and psychoactive drugs Phytopharmacology and psychoactive substances Drug treatment of neurological disorders Mechanisms of action of psychotropic drugs Ethnopsychopharmacology Pharmacogenetic aspects of mental illness and drug response Psychometrics: psychopharmacological methods and experimental design Human Psychopharmacology comprises Original Articles, Short Communications (not exceeding 1500 words) and Reviews. Editorials are by invitation, but suggestions are welcome. Editorial Policy The Editorial policy is to publish contributions on all aspects of psychopharmacology relevant to human experimental research and clinical medicine. Human Psychopharmacology is a multi-disciplinary journal that covers all aspects from clinical and social issues to experimental laboratory based studies that are of relevance to clinical psychopharmacology. All articles are strictly refereed and only those meeting acceptable ethical standards governing experimentation on humans will be considered for publication. The Editors are particularly pleased to consider publishing the proceedings of symposia as supplements to the journal, providing they meet the strict editorial criteria. It is the intention of the Editors to publish contributions within three to six months from the date of final acceptance.
From the journal's Aims & Scope
Research area (LetPub): Psychiatry
Editor-in-chief David Baldwin SouthamptonPublisher website
Editorial board by country: 2 in mainland China (about 9%); most named United Kingdom 7, Mainland China 2, United States 2, Japan 2, Australia 2 (22 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Treatment of Major DepressionMedicine13.1%
- Schizophrenia research and treatmentMedicine11%
- Neurotransmitter Receptor Influence on BehaviorNeuroscience8.4%
- Attention Deficit Hyperactivity DisorderMedicine7.5%
- Anxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesPsychology5.8%
- Bipolar Disorder and TreatmentMedicine5.7%
- Tryptophan and brain disordersNeuroscience4.9%
- Electroconvulsive Therapy StudiesMedicine4.2%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Clinical Neurology | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
| Minor | Psychiatry | Zone 4 |
| Minor | Psychology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Clinical Neurology | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
| Minor | Psychiatry | Zone 4 |
| Minor | Psychology | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Clinical Neurology | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
| Minor | Psychiatry | Zone 4 |
| Minor | Psychology | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
Web of ScienceMEDLINEPubMedEmbasePsycINFOCASCAB AbstractsCurrent ContentsPublisher website
Other: EBSCO, ProQuest
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 1.95LetPub ·
- Impact factor (publisher)
- 2Publisher website ·
- Impact factor (publisher) 2025
- 2Publisher website ·
- CiteScore 2026-06
- 4.5LetPub ·
- CiteScore (publisher)
- 4.5Publisher website ·
- CiteScore (publisher) 2025
- 4.5Publisher website ·
- SJR 2026-06
- 0.66LetPub ·
- SNIP 2026-06
- 0.96LetPub ·
- h-index
- 72LetPub ·
- h-index
- 102OpenAlex ·
- i10-index
- 1,498OpenAlex ·
- 2-year mean citedness
- 1.09OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 53.13%LetPub ·
Volume
- Articles per year
- 22LetPub ·
- Articles per year (publisher) 2025
- 25Publisher website ·
- Downloads per year (publisher) 2025
- 174,353Publisher website ·
Articles by year OpenAlex count · 3,611 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 44 | 20 | 9 |
| 2025 | 37 | 22 | 47 |
| 2024 | 35 | 19 | 70 |
| 2023 | 34 | 23 | 151 |
| 2022 | 38 | 13 | 278 |
| 2021 | 60 | 25 | 504 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
112 daysMedian, submission to acceptance · P25–P75 77 days – 169 days
- Acceptance to online
- median 10 days (63 articles)
- Submission to online
- median 138 days
- Sample
- 63 articles with submission and acceptance dates (75 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 6–12 weeksLetPub ·
- Average acceptance (community reports)
- Fairly easyLetPub ·
- Acceptance rate (publisher)
- 32%Publisher website ·
- Acceptance rate (publisher) 2025
- 32%Publisher website ·
- Submission to first decision
- 6 daysPublisher website ·
- Submission to first decision 2025
- 6 daysPublisher website ·
- Submission to acceptance 2025
- 133 daysPublisher website ·
- Acceptance to publication 2025
- 11 daysPublisher website ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 4,030 / EUR 3,350 / GBP 2,670 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Policy excerpts from the journal's websiteAuthorship, Preprints
- Authorship 2.2 Authorship and Acknowledgements
Authorship: Authors submitting a paper do so on the understanding that the manuscript has been read and approved by all authors and that all authors agree to the submission of the manuscript to the Journal.
Source ↗Publisher website ·- Preprints Preprint Policy
Human Psychopharmacology: Clinical and Experimental will consider for review articles previously available as preprints. Authors may also post the submitted version of a manuscript to a preprint server at any time. Authors are requested to update any pre-publication versions with a link to the final published article.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- John Wiley and Sons Ltd
- Country or region
- ENGLAND
- Language
- English
- Frequency
- Bimonthly
- Founded
- 1986
- ISSN
- 0885-6222
- Electronic ISSN
- 1099-1077
- Latest issue on the website
- Volume 41, Issue 5 (September 2026)
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
FAQ
Frequently asked questions about Human Psychopharmacology Clinical and Experimental
What CAS zone is Human Psychopharmacology Clinical and Experimental in?
In the 2025 upgraded edition of the CAS Journal Ranking, Human Psychopharmacology Clinical and Experimental is in Zone 4 of Medicine, and in Zone 4 of the minor category Clinical Neurology / Pharmacology & Pharmacy / Psychiatry / Psychology. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Human Psychopharmacology Clinical and Experimental?
The latest impact factor listed by LetPub is 1.95; CiteScore 4.5, h-index 102.
How long does peer review take at Human Psychopharmacology Clinical and Experimental?
Based on the dates recorded on 63 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 112 days (interquartile range 77–169 days); authors report an average review time of 6–12 weeks; the community-reported acceptance is “Fairly easy”; the journal's website gives an acceptance rate of 32% (2025). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Human Psychopharmacology Clinical and Experimental based?
Of the 22 board members whose country the journal's board page names, 2 (about 9%) are in mainland China; the countries named most often are United Kingdom (7), Mainland China (2) and United States (2). Counted from the institutions listed on the board page; for reference only.
Which databases index Human Psychopharmacology Clinical and Experimental?
According to LetPub and DOAJ records, Human Psychopharmacology Clinical and Experimental is indexed in SCIE and Scopus. The journal's website also lists Web of Science, MEDLINE, PubMed, Embase, PsycINFO, CAS, CAB Abstracts and Current Contents; that list has not been checked against each database.
Is Human Psychopharmacology Clinical and Experimental open access, and what is the APC?
Human Psychopharmacology Clinical and Experimental is a hybrid journal. For open-access publication: APC about USD 4,030.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .